Mayo Clinic
The purpose of this study is to evaluate the efficacy and safety of Avacopan together with low-dose glucocorticoid in the treatment of patients with crescentic Imunoglobulin A Nephropathy (IgAN) and high risk of progression.
Inclusion Criteria * Age \> 18 years * Kidney biopsy showing crescentic IgA nephropathy within 6 months of enrolment (MEST-C-score =C1/C2). * Quantified creatinine clearance \>20 ml/min/1.73m2 * Quantified Proteinuria \> 750 mg/24h based on a 24h urine collection while on maximum tolerated dose of RAS blockade * Hematuria defined as \>10 RBC/hpf or hemoglobinuria \>1+ * Patients need to be in adequate supportive care (blood pressure \<125/85mmHg, lifestyle advice, and maximum doses tolerable of RAS blockade) at least 4 weeks prior to enrollment * Patients would receive dietary and lifestyle c…
Avacopan is a complement 5a receptor (C5aR) antagonist, orally active.
0.4 mg/kg per day (maximum, 32 mg/day) for 2 months followed by dose tapering by 4 mg per day each month (total duration 6-9 months
Methylprednisolone 1g intravenous on day +1
Prednisone 0.2 mg/kg per day (maximum, 16 mg/day) for 2 months followed by dose tapering by 2 mg per day each month (total duration 6-9 months)
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.